Navigation Links
Kendle Executive to Share Insights at World Pharma Trials Asia 2010
Date:3/17/2010

CINCINNATI, March 17 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Dr. Ross Horsburgh, Vice President, Asia/Pacific will address the World Pharma Trials Asia 2010 conference being held March 17-18, 2010 at the Raffles City Convention Centre in Singapore. Dr. Horsburgh's presentation, "Accelerating Oncology Clinical Development in Asia," is scheduled for March 18 at 2 p.m. local time.  World Pharma Trials Asia brings together pharmaceutical companies, biotechnology companies and CROs to explore outsourcing opportunities in Asia.

Dr. Horsburgh's presentation will explore key opportunities and challenges in oncology development in the region, discuss the benefits of including Asian countries in global development plans for oncology, define key success factors for conducting these trials in Asia and discuss best practices in selecting the optimal sites for exploratory oncology trials.  

Following the conference, Dr. Horsburgh's presentation will be posted to the Kendle Web site at http://www.kendle.com/RW_media_show.php?cid=6.

Dr. Horsburgh is a trained medical physician with more than 20 years of experience in the CRO and pharmaceutical industries.  He is responsible for the strategic oversight of all of Kendle's operations throughout the Asia/Pacific region, which includes offices in Beijing, Hong Kong and Shanghai, China; Ahmedabad and New Delhi, India; Kuala Lumpur, Malaysia; Bangkok, Thailand; Manila, Philippines; Sydney and Melbourne, Australia and Singapore.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.

SOURCE Kendle International Inc.

Back to top

RELATED LINKS
http://www.kendle.com

'/>"/>

SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
2. Kendle Launches New Global Biostatistics Infrastructure
3. Kendle Receives Approval From Indian Government to Proceed With Development of Operations Center in Special Economic Zone
4. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
5. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
6. Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition
7. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
8. ThermalTherapeutic Systems, Inc. Announces the Addition of Former MEDRAD Executive Alan Hirschman, PhD to the Board of Directors
9. Yvonne Verburgt Joins the Avrio Executive Team as Vice President of Business Development and Marketing
10. Top Bristol-Myers Squibb Executive Joins Patton Boggs
11. Babson Executive Education Offers Bio-Pharma: Mastering the Business of Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales ... cannabis is legal will generate $655 million in taxes on retail ... specific taxes, such as Washington State,s 37% ... from state sales taxes that are applied on all retail sales. ...
(Date:3/27/2017)... March 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ... 8IS) Invictus MD is pleased to announce it has ... trading on the TSX Venture Exchange.  ... a year of significant achievements for Invictus-MD. Some of ... crops at AB Laboratories Inc. ("AB Labs"), a Licensed ...
(Date:3/27/2017)... BOSTON , March 27, 2017 /PRNewswire/ ... through a data-driven, biological research approach, today ... contributed to the discovery of new data ... and facilitate brown fat metabolism. Joslin Diabetes ... its Interrogative Biology® platform for analysis of ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding ... Pennsylvania. , The program, developed in association with efforts by the American College ...
(Date:3/28/2017)... San Diego, CA (PRWEB) , ... March 28, 2017 , ... ... and turtlenecks from the daily wardrobe. However, for those self-conscious about a double chin, ... believe they have the ideal solution. , “For most people, a double chin ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, ... to ensuring high-quality results and maintaining GMP and USP compliance. In a new ... accordance with GMP requirements " these requirements are explained. The challenge is ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm ... its corporate headquarters to a new, more expansive office space in order to ... Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 Silas ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 ... access to quality care can be limited while the desire to conquer breakouts and ... prescription acne care for every customer online, today released its inaugural survey on the ...
Breaking Medicine News(10 mins):